ADVERTISEMENT

Is The Price Of Ozempic Really So Outrageous?

US Senator Bernie Sanders may think Novo Nordisk is charging too much for its blockbuster obesity drug, but innovation isn’t cheap.

<div class="paragraphs"><p>(Photographer: George Frey/Bloomberg)</p></div>
(Photographer: George Frey/Bloomberg)
GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of controversy, with the chief executive of Novo Nordisk, the maker of Ozempic and Wegovy, scheduled to testify today before Congress. The title of the hearing leaves little to the imagination: “Why Is Novo Nordisk Charging Americans with Diabetes and Obesity Outrageously High Prices for Ozempic and Wegovy?”One an...
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More